Page results
-
Mixed sex accommodation and privacy information for patients coming into hospital for an inpatient stay
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
All GPs are now welcome to use our national Infectious & Tropical Disease Advice and Guidance function on the e-referral system (NHS e-RS)
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
File results
-
FOI/2024/0582 - SACT (systemic anti-cancer therapy) treatments for endometrial cancer
-
FOI/2024/0583 - National inpatient survey improvements/ night-time noise levels/ ward lighting/ mealtime support
-
FOI/2024/0584 - Immunology Hidradenitis Suppurativa (HS) treatments
-
FOI/2024/0586 - Subject Access Requests (SAR) and Freedom of Information (FOI) requests for 2023/24
-
FOI/2024/0587 - Colorectal cancer treatments
-
FOI/2024/0589 - SACT Cancer report/ Drug Patient Level Contract Monitoring (DrPLCM) report
-
FOI/2024/0594 - Implementation of Federated Data Platform (FDP) and procurement of data platforms
-
FOI/2024/0595 - Capital estate activity for 2020-2024
-
FOI/2024/0597 - Urothelial cancer treatments
-
FOI/2024/0605 - Finance software system/ installation and expiry of software